Orally bioavailable selective GPR119 agonist (EC50 value 44 nM for hGPR119, IC50 value 13 μM) with a good balance between agonist potency, intrinsic activity, metabolic profile and in particular on its good solubility and reduced drug–drug interaction potential. In clinical trial, JNJ 38431055 was well tolerated and not associated with hypoglycaemia.

KEYWORDS: APD 597 | supplier | GPR119 agonist | JNJ 38431055 | APD597 | JNJ38431055 | CAS [897732-93-3] | [897732-74-0] | Cannabinoids | GPR119 | Agonist | diabetes melitus | T2DM |  insulin | incretin | glucose | glucagon | cAMP